Format

Send to

Choose Destination
J Exp Med. 2019 Jun 3;216(6):1234-1243. doi: 10.1084/jem.20181739. Epub 2019 Apr 25.

Modulating inflammation for cancer therapy.

Author information

1
Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt/Main, Germany.
2
Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt/Main, Germany greten@gsh.uni-frankfurt.de.
3
Frankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt/Main, Germany.
4
German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany.

Abstract

A link between chronic inflammation and development of tumors is well established. Moreover, it has become evident that tumorigenesis is not a cell autonomous disease, and an inflammatory microenvironment is a prerequisite of basically all tumors, including those that emerge in the absence of overt inflammation. This knowledge has led to the development of anti-inflammatory concepts to treat and prevent cancer. In contrast, immunotherapies, in particular checkpoint inhibitors, representing the most significant progress in the therapy of several malignancies depend on the presence of a pro-inflammatory "hot" environment. Here, we discuss pro- and anti-inflammatory concepts for the treatment of cancer.

PMID:
31023715
PMCID:
PMC6547855
[Available on 2019-12-03]
DOI:
10.1084/jem.20181739

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center